Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pulmonary drug delivery sales set to double:

This article was originally published in Clinica

Executive Summary

In four years' time, worldwide sales of pulmonary drug delivery products will have almost doubled to $15.2 billion, says a recent report from Front Line Strategic Management Consulting (Foster City, California). Average growth of 13% per year is expected, with new technologies, such as dry powder inhalers, and the phasing out of CFC systems and displacement of injectable therapies, contributing to the rise in sales. In 2001, sales of this category of product amountable to $8.4 billion, says the report. The US accounts for 44% of worldwide sales. The larger number of asthma sufferers and a favourable reimbursement policy from third-party payers makes the US a lucrative market.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT073870

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel